Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project

The Lancet Infectious Diseases

Volumn 16, Issue 10, 2016, Pages 1185-1192

  Zignol, Matteo ^a   Dean, Anna S ^a   Alikhanova, Natavan ^b   Andres, Sönke ^c   Cabibbe, Andrea Maurizio ^d   Cirillo, Daniela Maria ^d   Dadu, Andrei ^a   Dreyer, Andries ^e   Driesen, Michèle ^f   Gilpin, Christopher ^a   Hasan, Rumina ^g   Hasan, Zahra ^g   Hoffner, Sven ^h,i   Husain, Ashaque ^j   Hussain, Alamdar ^k   Ismail, Nazir ^e,l   Kamal, Mostofa ^m   Mansjö, Mikael ^h   Mvusi, Lindiwe ⁿ   Niemann, Stefan ^c   Omar, Shaheed V ^e   Qadeer, Ejaz ^o   Rigouts, Leen ^f,p   Ruesch Gerdes, Sabine ^c   Schito, Marco ^q   Seyfaddinova, Mehriban ^b   Skrahina, Alena ^r   Tahseen, Sabira ^k   Wells, William A ^s   Mukadi, Ya Diul ^s   Kimerling, Michael ^t   Floyd, Katherine ^a   Weyer, Karin ^a   Raviglione, Mario C ^a   more..

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Research Scientific Institute of Lung Diseases   (Azerbaijan)

^c Supranational Reference Laboratory   (Germany)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^g AGA KHAN UNIVERSITY   (Pakistan)

^h SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j National Tuberculosis Control Programme   (Bangladesh)

^k National Tuberculosis Control Programme   (Pakistan)

^l UNIVERSITY OF PRETORIA   (South Africa)

^m National Institute of Diseases of Chest and Hospital   (Bangladesh)

ⁿ NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^o National Emergency Operation Centre   (Pakistan)

^p UNIVERSITY OF ANTWERP   (Belgium)

^q CRITICAL PATH INSTITUTE   (United States)

^r Republican Scientific and Practical Center for Pulmonology and Tuberculosis   (Belarus)

^s UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^t KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; AZERBAIJAN; BANGLADESH; BELARUS; DRUG SURVEILLANCE PROGRAM; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR EPIDEMIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PAKISTAN; PNCA GENE; PRIORITY JOURNAL; SOUTH AFRICA; TUBERCULOSIS; ASIA; DRUG EFFECTS; HEALTH SURVEY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; RETROSPECTIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; ASIA; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; PYRAZINAMIDE; RETROSPECTIVE STUDIES; RIFAMPIN; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84990064441     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30190-6     Document Type: Article

References (33)

1. 1 Global tuberculosis report 2015. WHO/HTM/TB/2015.22, 2015, World Health Organization, Geneva.
2. 2 Getahun, H, Matteelli, A, Abubakar, I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 46 (2015), 1563–1576.
3. 3 Caminero, JA, Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 14 (2010), 382–390.
4. 4 Monedero, I, Caminero, JA, Common errors in multidrug-resistant tuberculosis management. Expert Rev Respir Med 8 (2014), 15–23.
5. 5 Merle, CS, Fielding, K, Sow, OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371 (2014), 1588–1598.
6. 6 Gillespie, SH, Crook, AM, McHugh, TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371 (2014), 1577–1587.
7. 7 Jindani, A, Harrison, TS, Nunn, AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371 (2014), 1599–1608.
8. 8 Guidelines for treatment of tuberculosis. WHO/HTM/TB/2009.420, 4th edn., 2009, World Health Organization, Geneva.
9. 9 Dawson, R, Diacon, AH, Everitt, D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385 (2015), 1738–1747.
10. 10 Aung, KJM, Van Deun, A, Declercq, E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18 (2014), 1180–1187.
11. 11 WHO. Treatment guidelines for drug-resistant tuberculosis. 2016 update. WHO/HTM/TB/2016.04, 2016, World Health Organization, Geneva.
12. 12 Nuermberger, E, Tyagi, S, Tasneen, R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52 (2008), 1522–1524.
13. 13 Wells, WA, Boehme, CC, Cobelens, FGJ, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 13 (2013), 449–458.
14. 14 WHO. Guidelines for surveillance of drug resistance in tuberculosis. WHO/TB/2015.13, 5th edn., 2015, World Health Organization, Geneva.
15. 15 Alikhanova, N, Akhundova, I, Seyfaddinova, M, et al. First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis. Public Health Action 4 (2014), S17–S23.
16. 16 Kamal, SMM, Hossain, A, Sultana, S, et al. Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey. Int J Tuberc Lung Dis 19 (2015), 151–156.
17. 17 Tahseen, S, Qadeer, E, Khanzada, FM, et al. Use of Xpert MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. Int J Tuberc Lung Dis 20 (2016), 448–455.
18. 18 Skrahina, A, Hurevich, H, Zalutskaya, A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 39 (2012), 1425–1431.
19. 19 South African Tuberculosis Drug Resistance Survey 2012–2014. Sandringham, South Africa, National Institute for Communicable Diseases. http://www.nicd.ac.za (accessed June 28, 2016).
20. 20 Whitfield, MG, Warren, RM, Streicher, EM, et al. Mycobacterium tuberculosis pncA polymorphisms that do not confer pyrazinamide resistance at a breakpoint concentration of 100 micrograms per milliliter in MGIT. J Clin Microbiol 53 (2015), 3633–3635.
21. 21 Miotto, P, Cabibbe, AM, Feuerriegel, S, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio 5 (2014), e01819–e01820.
22. 22 Feuerriegel, S, Schleusener, V, Beckert, P, et al. PhyResSE: a web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J Clin Microbiol 53 (2015), 1908–1914.
23. 23 Sandgren, A, Strong, M, Muthukrishnan, P, Weiner, BK, Church, GM, Murray, MB, Tuberculosis drug resistance mutation database. PLoS Med, 6, 2009, e2.
24. 24 Broad Institute. Tuberculosis drug resistance mutation database. http://www.broadinstitute.org/annotation/genome/mtb_drug_resistance.1/DirectedSequencingHome.html (accessed Dec 18, 2015).
25. 25 WHO. Updated interim critical concentrations for first-line and second-line DST, 2012, World Health Organization, Geneva.
26. 26 Denkinger, CM, Dolinger, D, Schito, M, et al. Target product profile of a molecular drug-susceptibility test for use in microscopy centers. J Infect Dis 211:suppl 2 (2015), S39–S49.
27. 27 Wells, WA, Ge, CF, Patel, N, Oh, T, Gardiner, E, Kimerling, ME, Size and usage patterns of private TB drug markets in the high burden countries. PLoS One, 6, 2011, e18964.
28. 28 Isaeva, Y, Bukatina, A, Krylova, L, Nosova, E, Makarova, M, Moroz, A, Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system. J Antimicrob Chemother 68 (2013), 2274–2281.
29. 29 Rigouts, L, Coeck, N, Gumusboga, M, et al. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother 71 (2016), 314–323.
30. 30 Willby, M, Sikes, RD, Malik, S, Metchock, B, Posey, JE, Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 59 (2015), 5427–5434.
31. 31 Gumbo, T, Chigutsa, E, Pasipanodya, J, et al. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother 69 (2014), 2420–2425.
32. 32 Zhang, Y, Yew, W-W, Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis 19 (2015), 1276–1289.
33. 33 Ramirez-Busby, SM, Valafar, F, Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 59 (2015), 5267–5277.